Longitudinal sequencing of matched primary and lung metastatic specimens has confirmed early NF2 loss with subsequent accumulation of alterations in BRCA2, SETD2, ATM, and Beta-2-microglobulin, along with increased tumor mutational burden, implying progressive genomic instability and immune-evasion mechanisms [35,36]. The gene discussed is NF2; the disease is neoplasm.